


**AMENDMENTS TO THE SPECIFICATION**


This listing of amended paragraphs will replace all prior versions of the paragraphs in the application.

***Listing of Amended Paragraphs:***

Replace the paragraph and accompanying figure bridging pages 46, lines 17-24, and 47, lines 1-9, of the specification with the following amended paragraph:

-- Unless otherwise indicated, the term "heteroaryl" as used herein alone or as part of another group refers to a 5-, 6- or 7- membered aromatic ring which includes 1, 2, 3 or 4 hetero atoms such as nitrogen, oxygen or sulfur, and such rings fused to an aryl, cycloalkyl, heteroaryl or cycloheteroalkyl ring (e.g. benzothiophenyl, indolyl), and includes possible N-oxides, ~~linked through a carbon atom or a heteroatom, where possible, optionally via the linker (CH<sub>2</sub>)<sub>q</sub> (where q is 0, 1, 2 or 3).~~ The heteroaryl group may optionally include 1 to 4 substituents such as any of the substituents for alkyl or aryl set out above. Examples of heteroaryl groups include the following:





and the like. --

Please replace the fourth full paragraph on page 67, lines 20-22, of the specification with the following amended paragraph:

-- Compounds of formula I of the invention may also inhibit AP-1 activity as indicated in cellular transrepressional ~~transrepressional~~ assays, and cause none to minimal transactivation as indicated in cellular transcriptional ~~transcriptional~~ assays. --

Please replace the fifth full paragraph on page 67, lines 23-26, of the specification with the following amended paragraph:

-- The GR binding assay, cellular transrepressional ~~transrepressional~~ assay and cellular transcriptional assay employed are described in copending provisional application No. 60/396,907, filed July 18, 2002, (~~attorney docket D0250-PSP~~) which is incorporated herein by reference. --